Bringing a genomic perspective to the safety of drug treatment in oncology

Research output: Research - peer-reviewReview article

Abstract

This article describes the clinical relevance of toxicity of therapies administered to patients with cancer, putting the patient, rather than disease, at the center of the evaluation of safety of anti-cancer therapy. Hence, the implications of adverse events are described from the patient perspective, focusing on the impact of patient safety on quality of life and efficacy of treatment. Issues revolving around other types of safety, such as financial toxicity, are also discussed. The role played by genetics in the assessment of a patient's risk of adverse events is also discussed, both in relation to the potential of genomic research and in the context of current tools of fruition in clinical care.

LanguageEnglish (US)
Article number385
JournalF1000Research
Volume6
DOIs
StatePublished - 2017

Fingerprint

Safety
Pharmaceutical Preparations
Therapeutics
Drug therapy
Oncology
Toxicity
Neoplasms
Genetics
Patient Safety
Quality of Life
Research

Keywords

  • Anti-cancer therapies
  • Genetics
  • Genomics
  • Oncology
  • Toxicity

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Bringing a genomic perspective to the safety of drug treatment in oncology. / Innocenti, Federico.

In: F1000Research, Vol. 6, 385, 2017.

Research output: Research - peer-reviewReview article

@article{91eb1d1f660948fc968c5ec8d0ed2926,
title = "Bringing a genomic perspective to the safety of drug treatment in oncology",
abstract = "This article describes the clinical relevance of toxicity of therapies administered to patients with cancer, putting the patient, rather than disease, at the center of the evaluation of safety of anti-cancer therapy. Hence, the implications of adverse events are described from the patient perspective, focusing on the impact of patient safety on quality of life and efficacy of treatment. Issues revolving around other types of safety, such as financial toxicity, are also discussed. The role played by genetics in the assessment of a patient's risk of adverse events is also discussed, both in relation to the potential of genomic research and in the context of current tools of fruition in clinical care.",
keywords = "Anti-cancer therapies, Genetics, Genomics, Oncology, Toxicity",
author = "Federico Innocenti",
year = "2017",
doi = "10.12688/f1000research.10475.1",
volume = "6",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Bringing a genomic perspective to the safety of drug treatment in oncology

AU - Innocenti,Federico

PY - 2017

Y1 - 2017

N2 - This article describes the clinical relevance of toxicity of therapies administered to patients with cancer, putting the patient, rather than disease, at the center of the evaluation of safety of anti-cancer therapy. Hence, the implications of adverse events are described from the patient perspective, focusing on the impact of patient safety on quality of life and efficacy of treatment. Issues revolving around other types of safety, such as financial toxicity, are also discussed. The role played by genetics in the assessment of a patient's risk of adverse events is also discussed, both in relation to the potential of genomic research and in the context of current tools of fruition in clinical care.

AB - This article describes the clinical relevance of toxicity of therapies administered to patients with cancer, putting the patient, rather than disease, at the center of the evaluation of safety of anti-cancer therapy. Hence, the implications of adverse events are described from the patient perspective, focusing on the impact of patient safety on quality of life and efficacy of treatment. Issues revolving around other types of safety, such as financial toxicity, are also discussed. The role played by genetics in the assessment of a patient's risk of adverse events is also discussed, both in relation to the potential of genomic research and in the context of current tools of fruition in clinical care.

KW - Anti-cancer therapies

KW - Genetics

KW - Genomics

KW - Oncology

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85017119965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017119965&partnerID=8YFLogxK

U2 - 10.12688/f1000research.10475.1

DO - 10.12688/f1000research.10475.1

M3 - Review article

VL - 6

JO - F1000Research

T2 - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 385

ER -